Figure 1: Human PD-1 expression on T cells is confirmed by FACS analysis in the single KI HuGEMM model.
The HuGEMM PD-1/OX40 mouse provides a translational humanized drug target mouse model for testing human-specific combination therapies. The double knock-in model has both humanized PD-1 and OX40 receptors within a functional mouse immune system.
The PD-1/OX40 double knock-in model was developed by breeding the PD-1 HuGEMM, a chimeric model generated via knock-in of human exon 2 and 3 of the PD-1 gene, and the OX40 HuGEMM, a model generated by replacing the entire mOX40 coding region with the human counterpart.
- Evaluate your human-specific combinations of anti-PD-1/anti-OX40 therapies in vivo
- Save study resources by using a cost effective alternative to more complex fully humanized models
Model Characterization Data
Human transgene expression was validated via FACS in the PD-1 (Figure 1) and OX40 single KI HuGEMM model.
Figure 1: Human PD-1 expression on T cells is confirmed by FACS analysis in the single KI HuGEMM model.
×
Figure 2: Validation of efficacy of human-specific anti-PD-1 and anti-OX40 antibodies: Combination anti-PD-1 + anti-OX40 yields a better response than single agent treatments, with 5/7 mice cured in the combo group
Figure 2: Validation of efficacy of human-specific anti-PD-1 and anti-OX40 antibodies: Combination anti-PD-1 + anti-OX40 yields a better response than single agent treatments, with 5/7 mice cured in the combo group
